deltatrials
Completed PHASE1/PHASE2 INTERVENTIONAL 1-arm NCT03315039

Study of Liposomal Annamycin for the Treatment of Subjects With Acute Myeloid Leukemia (AML)

Phase 1/2 Study of Liposomal Annamycin for the Treatment of Subjects With Acute Myeloid Leukemia (AML) That is Refractory to or Relapsed After Standard Induction Therapy

Sponsor: Moleculin Biotech, Inc.

Conditions Leukemia, Myeloid, Acute
Interventions Liposomal Annamycin
Updated 16 times since 2017 Last updated: Feb 28, 2022 Started: Mar 28, 2018 Primary completion: Jan 14, 2020 Completion: Jun 20, 2020
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1/PHASE2 trial investigates Leukemia, Myeloid, Acute and is currently completed. Moleculin Biotech, Inc. leads this study, which shows 16 recorded versions since 2018 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

~Nov 2017 – ~Apr 2018 · 5 months · monthly snapshot~Apr 2018 – ~May 2018 · 30 days · monthly snapshot~May 2018 – ~Jun 2018 · 31 days · monthly snapshot~Jun 2018 – ~Aug 2018 · 2 months · monthly snapshot~Aug 2018 – ~Jan 2019 · 5 months · monthly snapshot~Jan 2019 – ~Sep 2019 · 8 months · monthly snapshot~Sep 2019 – ~Jan 2020 · 4 months · monthly snapshot~Jan 2020 – ~May 2020 · 4 months · monthly snapshot~May 2020 – ~Jan 2021 · 8 months · monthly snapshot~Jan 2021 – ~Mar 2021 · 59 days · monthly snapshot~Mar 2021 – ~Sep 2021 · 6 months · monthly snapshot~Sep 2021 – ~Mar 2022 · 6 months · monthly snapshot~Mar 2022 – ~Apr 2022 · 31 days · monthly snapshot~Apr 2022 – ~Jul 2024 · 27 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – present · 24 months · monthly snapshot

Change History

16 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE1/PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE1/PHASE2

    Phase: PHASE1_PHASE2 → PHASE1/PHASE2

  3. Apr 2022 — Jul 2024 [monthly]

    Completed PHASE1_PHASE2

  4. Mar 2022 — Apr 2022 [monthly]

    Completed PHASE1_PHASE2

  5. Sep 2021 — Mar 2022 [monthly]

    Completed PHASE1_PHASE2

    Status: Active Not Recruiting → Completed

▶ Show 11 earlier versions

  1. Mar 2021 — Sep 2021 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  2. Jan 2021 — Mar 2021 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  3. May 2020 — Jan 2021 [monthly]

    Active Not Recruiting PHASE1_PHASE2

    Status: Recruiting → Active Not Recruiting

  4. Jan 2020 — May 2020 [monthly]

    Recruiting PHASE1_PHASE2

  5. Sep 2019 — Jan 2020 [monthly]

    Recruiting PHASE1_PHASE2

  6. Jan 2019 — Sep 2019 [monthly]

    Recruiting PHASE1_PHASE2

  7. Aug 2018 — Jan 2019 [monthly]

    Recruiting PHASE1_PHASE2

  8. Jun 2018 — Aug 2018 [monthly]

    Recruiting PHASE1_PHASE2

  9. May 2018 — Jun 2018 [monthly]

    Recruiting PHASE1_PHASE2

  10. Apr 2018 — May 2018 [monthly]

    Recruiting PHASE1_PHASE2

    Status: Not Yet Recruiting → Recruiting

  11. Nov 2017 — Apr 2018 [monthly]

    Not Yet Recruiting PHASE1_PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Moleculin Biotech, Inc.
Data source: Moleculin Biotech, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations